Literatur
- 1
American Society
of Clinical Oncology .
American Society of Clinical Oncology
recommendations for the use of hematopoietic colony-stimulating
factors: evidence-based, clinical practice guidelines.
J
Clin Oncol.
1994;
12
2471-2508
- 2
American Society of Clinical
Oncology .
Update of recommendations for the use of
hematopoietic growth factors.
J Clin Oncol.
1996;
14
1957-1960
- 3
Anaissie E J, Kontoyiannis D P, O’Brien S, Kantarjian H, Robertson L, Lerner S, Keating M J.
Infections
in patients with chronic lymphocytic leukemia treated with fludarabine.
Ann
Intern Med.
1998;
129
559-566
- 4
Bergmann L. et al .
Fludarabine versus fludarabine plus epirubicin
in the treatment of chronic lymphocytic leukemia - preliminary
results of a randomized phase III multicenter study.
Ann
Oncol.
1999;
10
126
(suppl 3))
- 5
Bosch F, Perales M, Cobo F. et al .
Fludarabine,
cyclophosphamide and mitoxantrone (FMC) therapy in resistant or
relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma
(FL) abstr.
Blood.
1997;
90
2360
(Suppl 1))
- 6
Buhmann R, Nolte A. et al .
CD40-Activated
B-Cell Chronic Lymphocytic Leukemia Cells for Tumor Immunotherapy.
Blood.
1999;
93
1992-2002
- 7
Byrd J C, Rai K R, Sausville E A, Grever M.
Old and new therapies
in chronic lymphocytic leukemia.
Semin Oncol.
1998;
25
65-74
- 8
Byrd J C, Rai K R, Sausville E A, Grever M R.
Old and new
therapies in chronic lymphocytic leukemia.
Semin Oncol.
1998;
25
66-74
- 9
Cheson B D.
New
prospects in the treatment of indolent lymphomas with purine analogues.
Cancer
J Sci Am.
1998;
4
S27-36
- 10
Cheson B D.
Therapy
for previously untreated chronic lymphocytic leukemia: a reevaluation.
Semin
Hematol.
1998;
35
14-21
- 11
Cheson B D, Frame J N, Vena D, Quashu N, Sorensen J M.
Tumor
lysis syndrome: an uncommon complication of fludarabine therapy
of chronic lymphocytic leukemia.
J Clin Oncol.
1998;
16
2313-2320
- 12
CLL trialists’ collaborative
group .
Chemotherapeutic options in chronic lymphocytic
leukemia.
J Natl Cancer Inst.
1999;
91
861-868
- 13
Cooperative group for the
study of Immunoglobulin in chronic lymphocytic leukemia .
Intravenous
immunoglobulin for the prevention of infection in chronic lymphocytic
leukemia.
N Engl J Med.
1988;
319
902-907
- 14
Diehl L F, Ketchum L H.
Autoimmune
disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia,
pure red cell aplasia, and autoimmune thrombocytopenia.
Semin
Oncol.
1998;
25
80-97
- 15
Dreger P, von Neuhoff N, Sonnen R, Kuse R, Viehmann K, Glass B, Kneba M, Schmitz N.
Factors
determining feasibility and outcome of autologous stem cell transplantation
for CLL (abstr.)
Ann Oncol.
1999;
10
25
(Suppl 3))
- 16
Johnson S, Smith A G, Löffler H. French Cooperative Group on CLL .
Multicentre prospective
randomised trial of fludarabine versus cyclophosphamide, doxorubicine,
and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic
leukemia.
Lancet.
1996;
347
1432-1438
- 17
Hallek M. et al .
GCLLSG. Fludarabine plus cyclophosphamide
(FC) and dose-intensified chlorambucil (DIC) for the treatment of
chronic lymphocytic leukemia (CLL).
Ann Oncol.
1999;
10
67
(Suppl 3))
- 18
Han T. et
al .
Chlorambucil vs combined chlorambucil-corticosteroid
therapy in chronic lymphocytic leukemia.
Cancer.
1973;
31
502-508
- 19
Hansen M M.
Chronic
lymphocytic leukaemia.
Scand J Haematol.
1973;
18
283-286
(Suppl))
- 20
Hudson R P, Wilson S L.
Hypogammaglobulinemia
and chronic lymphatic leukemia.
Cancer.
1960;
13
200-204
- 21
Jaksic B, Brugiatelli M, Krc I. et al .
High dose chlorambucil versus Binet’s modified
cyclophosphamide, doxorubicin, vincristin, and prednisone regimen
in the treatment of patients with advanced B-cell chronic lymphocytic
leukemia.
Cancer.
1997;
79
2107-2114
- 22
Juliusson G, Liliemark J.
High complete remission
rate 2-chloro-2’-deoxyadenosine in previously treated patients
with B-cell chronic lymphocytic leukemia.
J Clin Oncol.
1993;
11
679-689
- 23
Kato K, Cantwell M J, Sharma S, Kipps T J.
Gene
transfer of CD40-ligand induces autologous immune recognition of
chronic lymphocytic leukemia B cells.
J Clin Invest.
1998;
101
1133-1141
- 24
Keating M J, O’Brien S, Lerner S. et al .
Long-term follow up of patients with chronic
lymphocytic leukemia (CLL) receiving fludarabine regimens as initial
therapy.
Blood.
1998;
92
1165-1171
- 25
Kipps T, Wierda W G, Woods S, Cantwell M J, Prussak C, Rassenti L Z.
Gene therapy
of leukemias and lymphomas.
Ann Oncol.
1999;
10
37
(Suppl 3))
- 26
Langenmayer I, Nerl C, Knauf W. et
al .
Interferon alpha 2b in the treatment of early stage
CLL with risk for progression. Results of a randomized multicenter
study.
Br J Haematol.
1996;
94
362-369
- 27
Leporrier M, Chevret S, Cazin B. et al .
Randomized comparison of fludarabine, CAP
and ChOP, in 695 previously untreated stage B and C chronic lymphocytic
leukemia (CLL) patients.
Blood.
1997;
90
529a
(Suppl 1))
- 28
Mauro F R, Foa R. et al .
Clinical
characteristics and outcome of young chronic lymphocytic leukemia
patients.
Blood.
1999;
94
448-454
- 29
Michallet M, Archimboud E, Bandini G. et al .
HLA-identical sibling bone marrow transplantation
in younger patients with chronic lymphocytic leukemia.
Ann
Intern Med.
1996;
124
311-315
- 30
Molica S.
Progression
and survival studies in early chronic lymphocytic leukemia.
Blood.
1991;
78
895-899
- 31
Morrison V A.
The
infectious complications of chronic lymphocytic leukemia.
Semin
Oncol.
1998;
25
98-106
- 32
O’Brien S.
Clinical
challenges in chronic lymphocytic leukemia.
Semin Hematol.
1998;
35
22-26
- 33
O’Brien S, del G iglio A, Keating M.
Advances
in the Biology and Treatment of B-Cell Chronic Lymphocytic Leukemia.
Blood.
1995;
85
307-318
- 34
O’Brien S, Kantarjian H, Beran M. et al .
Fludarabine (FAMP) and cyclophosphamide
(CTX) therapy in chronic lymphocytic leukemia (CLL) (abst.).
Blood.
1996;
88
480a
(Suppl 1))
- 35
Osterborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, Mellstedt H.
Phase
II multicenter study of human CD52 antibody in previously treated
chronic lymphocytic leucemia.
J Clin Oncol.
1997;
15
1567-1574
- 36
Rai K R, Peterson B L, Appelbaum F R, Kolitz J, Elias L, Shepherd L, Hines J, Threatte G A,
Larson R A, Cheson B D, Schiffer C A.
Fludarabine
compared with chlorambucil as primary therapy for chronic lymphocytic
leukemia.
N Engl Med.
2000;
343
1759-1757
- 37
Robertson L E, O’Brien S. et al .
Fludarabine
plus doxorubicin in previously treated chronic lymphocytic leukemia.
Leukemia.
1995;
9
943-945
- 38
Rondelli D. et al .
2-Chlordeoxyadenosine in the treatment
of relapsed/refractory chronic lymphocytic disorders.
Eur
J Hematol.
1997;
58
46-50
- 39
Sawitsky A, Rai K R, Glidewell O, Silver R T.
Comparison
of daily versus intermittent chlorambucil and prednisone therapy
in the treatment of patients with chronic lymphocytic leukemia.
Blood.
1977;
50
1049-1059
- 40
Seymour J F. et al .
Survival of young patients with chronic
lymphocytic leukemia faling fludarabine therapy.
Leuk
Lymphoma.
1995;
18
493-496
- 41
Sorensen J M, Vena D A. et al .
Treatment
of refractory chronic lymphocytic leukemia with fludarabine phosphate
via the group C protocol mechanism of the National Cancer Institute.
J
Clin Oncol.
1997;
15
458-465
- 42
Waselenko J K, Flynn J M, Byrd J C.
Stem-cell
transplantation in chronic lymphocytic leukemia.
Semin
Oncol.
1999;
26
48-61
- 43
Wendtner C -M, Schmitt B, Wilhelm M. et al .
Redefining the therapeutic goals in chronic
lymphocytic leukemia.
Ann Oncol.
1999;
10
505-509
- 44
Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A.
Cytokine-release
syndrome in patients with B-cell chronic lymphocytic leukemia and high
lymphocyte counts after treatment with an anti-CD20 monoclonal antibody
(Rituximab, IDEC-C2B8).
Blood.
1999;
94
2217-2223
Korrespondenz
Prof. Dr. med. Michael Hallek
Medizinische Klinik III Klinikum der Universität
München Großhadern
Marchioninistraße 15
81377 München
